Display options
Cite
He C, Zhang S, He H, et al. Predictive value of plasma volume status for contrast-induced nephropathy in patients with heart failure undergoing PCI. ESC Heart Fail. 2021;8(6):4873-4881doi: 10.1002/ehf2.13681.
He, C., Zhang, S., He, H., You, Z., Lin, X., Zhang, L., Chen, J., & Lin, K. (2021). Predictive value of plasma volume status for contrast-induced nephropathy in patients with heart failure undergoing PCI. ESC heart failure, 8(6), 4873-4881. https://doi.org/10.1002/ehf2.13681
He, Chen, et al. "Predictive value of plasma volume status for contrast-induced nephropathy in patients with heart failure undergoing PCI." ESC heart failure vol. 8,6 (2021): 4873-4881. doi: https://doi.org/10.1002/ehf2.13681
He C, Zhang S, He H, You Z, Lin X, Zhang L, Chen J, Lin K. Predictive value of plasma volume status for contrast-induced nephropathy in patients with heart failure undergoing PCI. ESC Heart Fail. 2021 Dec;8(6):4873-4881. doi: 10.1002/ehf2.13681. Epub 2021 Oct 26. PMID: 34704403; PMCID: PMC8712793.
Copy Download .nbib Format: NLM
Share it on

ESC Heart Fail. 2021 Dec;8(6):4873-4881. doi: 10.1002/ehf2.13681. Epub 2021 Oct 26.

Predictive value of plasma volume status for contrast-induced nephropathy in patients with heart failure undergoing PCI.

ESC heart failure

Chen He, Sicheng Zhang, Haoming He, Zhebin You, Xueqin Lin, Liwei Zhang, Jiankang Chen, Kaiyang Lin

Affiliations

  1. Department of Geriatric Medicine, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fujian Key Laboratory of Geriatrics, Fujian Provincial Center for Geriatrics, Fuzhou, 350001, China.
  2. Department of Cardiology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fujian Provincial Key Laboratory of Cardiovascular Disease, Fuzhou, Fujian, 350001, China.

PMID: 34704403 PMCID: PMC8712793 DOI: 10.1002/ehf2.13681

Abstract

AIMS: Contrast-induced nephropathy remains a common complication of coronary procedure and increases poor outcomes, especially in patients with heart failure. Plasma volume expansion relates to worsening prognosis of heart failure. We hypothesized that calculated plasma volume status (PVS) might provide predictive utility for contrast-induced nephropathy in patients with heart failure undergoing elective percutaneous coronary intervention (PCI).

METHODS AND RESULTS: We enrolled 441 patients with heart failure undergoing elective PCI from 2012 to 2018. Pre-procedural estimated PVS by the Duarte's formula (Duarte-ePVS) and Kaplan-Hakim formula (KH-ePVS) were calculated for all patients. CIN was defined as an absolute serum creatinine (SCr) increase ≥0.5 mg/dL or a relative increase ≥25% compared with the baseline value within 48 h of contrast medium exposure. We assessed the association between PVS and CIN in patients with heart failure undergoing elective PCI. In 441 patients, 28 (6.3%) patients developed CIN. The median Duarte-ePVS was 4.44 (3.87, 5.13) and the median KH-ePVS was -0.03 (-0.09, 0.05). The best cutoff values for Duarte-ePVS and KH-ePVS to predict CIN were 4.64 (with 78.6% sensitivity and 61.7% specificity) and 0.04 (with 64.5% sensitivity and 75.5% specificity), respectively. After adjusting for potential confounding variables, KH-ePVS > 0.04 [odds ratio (OR) 2.685, 95% confidence interval (CI) 1.012-7.123, P = 0.047] remained significantly associated with CIN whereas Duarte-ePVS was not.

CONCLUSIONS: Pre-procedural KH-ePVS is an independent risk factor for CIN in patients with heart failure undergoing elective PCI. The best cutoff point of KH-ePVS for predicting CIN was 0.04.

© 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Keywords: Contrast-induced nephropathy; Elective percutaneous coronary intervention; Heart failure; Plasma volume status

References

  1. J Am Coll Cardiol. 2004 Oct 6;44(7):1393-9 - PubMed
  2. J Clin Invest. 1946 Nov;25(6):848-57 - PubMed
  3. Am J Cardiol. 2018 Oct 1;122(7):1191-1194 - PubMed
  4. Heart. 2019 Jul;105(13):1020-1026 - PubMed
  5. Am J Med. 1997 Nov;103(5):368-75 - PubMed
  6. ESC Heart Fail. 2021 Dec;8(6):4873-4881 - PubMed
  7. Clin Res Cardiol. 2020 Nov;109(11):1392-1401 - PubMed
  8. Circulation. 2002 May 14;105(19):2259-64 - PubMed
  9. Can J Cardiol. 2016 Feb;32(2):247-55 - PubMed
  10. Eur J Heart Fail. 2015 Jan;17(1):35-43 - PubMed
  11. Eur J Heart Fail. 2020 Oct;22(10):1907-1911 - PubMed
  12. J Card Fail. 2018 Sep;24(9):553-560 - PubMed
  13. Circ J. 2013;77(7):1883-914 - PubMed
  14. Clin Res Cardiol. 2021 Aug;110(8):1159-1172 - PubMed
  15. Sci Rep. 2019 Oct 7;9(1):14369 - PubMed
  16. Clin Res Cardiol. 2020 Aug;109(8):1060-1069 - PubMed
  17. Int Heart J. 2019 Mar 20;60(2):247-254 - PubMed
  18. Eur J Heart Fail. 2019 May;21(5):634-642 - PubMed
  19. Eur J Heart Fail. 2016 Aug;18(8):891-975 - PubMed
  20. J Nucl Med. 1980 Aug;21(8):793-800 - PubMed
  21. Circulation. 1989 Aug;80(2):299-305 - PubMed
  22. Clin Res Cardiol. 2019 May;108(5):549-561 - PubMed
  23. BMJ. 2015 Aug 27;351:h4395 - PubMed
  24. J Am Coll Cardiol. 2002 Jun 19;39(12):1901-8 - PubMed
  25. Prog Cardiovasc Dis. 2003 May-Jun;45(6):493-503 - PubMed
  26. Eur Heart J. 2015 Jun 14;36(23):1437-44 - PubMed
  27. Eur Heart J Acute Cardiovasc Care. 2018 Jun;7(4):330-338 - PubMed
  28. JACC Heart Fail. 2015 Nov;3(11):886-93 - PubMed
  29. Nat Rev Nephrol. 2010 Feb;6(2):107-15 - PubMed
  30. J Am Coll Cardiol. 2009 Feb 17;53(7):589-596 - PubMed
  31. Radiology. 2012 Jun;263(3):706-13 - PubMed
  32. Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266 - PubMed
  33. Int Urol Nephrol. 2010 Dec;42(4):1049-54 - PubMed
  34. JAMA. 1996 May 15;275(19):1489-94 - PubMed
  35. J Cardiol. 2020 Jan;75(1):47-52 - PubMed
  36. J Am Heart Assoc. 2016 May 27;5(6): - PubMed

Publication Types

Grant support